Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 371 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results October 4, 2024 Does Sugar Feed Cancer? March 19, 2021 Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... July 3, 2024 “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... April 26, 2022 Load more HOT NEWS Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of... What Are Patient-Reported Outcomes and Why Are They Important in Cancer... Glucose Control Key in Reducing Cancer Risk for People with Type... What to Expect During Recovery From a Bone Marrow Transplant: An...
